Company Announcement
COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company’s website, www.genmab.com/investor-relations.
Conference Call
Genmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN: https://register.vevent.com/register/BI5982e6aa32af485f851860da1a450df3.
A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investor-relations.
2024 ACHIEVEMENTS
Business Progress
EPKINLY®/TEPKINLY® (epcoritamab) became the first and only subcutaneous (SC) bispecific antibody approved in both the U.S. and Europe to treat both relapsed or refractory follicular lymphoma (FL) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyAcquisition of ProfoundBio Inc. (ProfoundBio), granting Genmab worldwide rights to multiple candidates in development (including rinatabart sesutecan (Rina-S™)) plus ProfoundBio’s novel antibody-drug conjugate (ADC) technology platformsGenmab submitted a supplemental Japan New Drug Application (J-NDA) to the Ministry of Health, Labour and Welfare (MHLW) for SC EPKINLY for the treatment of relapsed or refractory FL after two or more lines of systemic therapyTivdak® (tisotumab vedotin-tftv) received full U.S. Food and Drug Administration (U.S. FDA) approval to treat recurrent or metastatic cervical cancerGenmab submitted a J-NDA to the MHLW for Tivdak for the treatment of advanced or recurrent cervical cancerGenmab assumed sole responsibility for the continued development and potential commercialization of
